Company Description
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery.
It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing.
The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents.
The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics.
This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal.
The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment.
The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019.
Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.
| Country | United States |
| Founded | 2002 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Raymond F. Vennare |
Contact Details
Address: 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 United States | |
| Phone | 412-432-1500 |
| Website | predictive-oncology.com |
Stock Details
| Ticker Symbol | POAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446159 |
| CUSIP Number | 74039M200 |
| ISIN Number | US74039M3097 |
| Employer ID | 33-1007393 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Raymond F. Vennare | Chief Executive Officer and Chairman |
| Joshua Blacher M.B.A. | Interim Chief Financial Officer |
| Theresa Ferguson | Senior Director of Marketing |
| Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Senior Vice President of Biologics |
| Dr. Arlette H. Uihlein FCAP, M.D. | Senior Vice President of Translational Medicine and Drug Discovery and Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K/A | [Amend] Current report |
| Feb 8, 2024 | 8-K | Current Report |
| Jan 4, 2024 | 8-K | Current Report |
| Dec 7, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 5, 2023 | PRE 14A | Other preliminary proxy statements |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |